Tags

Type your tag names separated by a space and hit enter

Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
Ann Neurol. 2011 Aug; 70(2):274-85.AN

Abstract

OBJECTIVE

There is a growing need to identify cerebrospinal fluid (CSF) markers that can detect Alzheimer's disease (AD) pathology in cognitively normal individuals because it is in this population that disease-modifying therapies may have the greatest chance of success. While AD pathology is estimated to begin ~10-15 years prior to the onset of cognitive decline, substantial neuronal loss is present by the time the earliest signs of cognitive impairment appear. Visinin-like protein-1 (VILIP-1) has demonstrated potential utility as a marker of neuronal injury. Here we investigate CSF VILIP-1 and VILIP-1/amyloid-β42 (Aβ42) ratio as diagnostic and prognostic markers in early AD.

METHODS

We assessed CSF levels of VILIP-1, tau, phosphorylated-tau181 (p-tau181), and Aβ42 in cognitively normal controls (CNC) (n = 211), individuals with early symptomatic AD (n = 98), and individuals with other dementias (n = 19). Structural magnetic resonance imaging (n = 192) and amyloid imaging with Pittsburgh Compound-B (n = 156) were obtained in subsets of this cohort. Among the CNC cohort, 164 individuals had follow-up annual cognitive assessments for 2-3 years.

RESULTS

CSF VILIP-1 levels differentiated individuals with AD from CNC and individuals with other dementias. CSF VILIP-1 levels correlated with CSF tau, p-tau181, and brain volumes in AD. VILIP-1 and VILIP-1/Aβ42 predicted future cognitive impairment in CNC over the follow-up period. Importantly, CSF VILIP-1/Aβ42 predicted future cognitive impairment at least as well as tau/Aβ42 and p-tau181/Aβ42.

INTERPRETATION

These findings suggest that CSF VILIP-1 and VILIP-1/Aβ42 offer diagnostic utility for early AD, and can predict future cognitive impairment in cognitively normal individuals similarly to tau and tau/Aβ42, respectively.

Links

PMC Free PDF
PMC Free Full Text
Aggregator Full Text

Authors+Show Affiliations

Tarawneh R
Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
D'Angelo G
No affiliation info available
Macy E
No affiliation info available
Xiong C
No affiliation info available
Carter D
No affiliation info available
Cairns NJ
No affiliation info available
Fagan AM
No affiliation info available
Head D
No affiliation info available
Mintun MA
No affiliation info available
Ladenson JH
No affiliation info available
Lee JM
No affiliation info available
Morris JC
No affiliation info available
Holtzman DM
No affiliation info available

MeSH

AdultAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedNeurocalcinPrognosisROC Curvetau Proteins

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21823155

Citation

Tarawneh, Rawan, et al. "Visinin-like Protein-1: Diagnostic and Prognostic Biomarker in Alzheimer Disease." Annals of Neurology, vol. 70, no. 2, 2011, pp. 274-85.
Tarawneh R, D'Angelo G, Macy E, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011;70(2):274-85.
Tarawneh, R., D'Angelo, G., Macy, E., Xiong, C., Carter, D., Cairns, N. J., Fagan, A. M., Head, D., Mintun, M. A., Ladenson, J. H., Lee, J. M., Morris, J. C., & Holtzman, D. M. (2011). Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Annals of Neurology, 70(2), 274-85. https://doi.org/10.1002/ana.22448
Tarawneh R, et al. Visinin-like Protein-1: Diagnostic and Prognostic Biomarker in Alzheimer Disease. Ann Neurol. 2011;70(2):274-85. PubMed PMID: 21823155.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. AU - Tarawneh,Rawan, AU - D'Angelo,Gina, AU - Macy,Elizabeth, AU - Xiong,Chengjie, AU - Carter,Deborah, AU - Cairns,Nigel J, AU - Fagan,Anne M, AU - Head,Denise, AU - Mintun,Mark A, AU - Ladenson,Jack H, AU - Lee,Jin-Moo, AU - Morris,John C, AU - Holtzman,David M, PY - 2011/8/9/entrez PY - 2011/8/9/pubmed PY - 2011/10/1/medline SP - 274 EP - 85 JF - Annals of neurology JO - Ann Neurol VL - 70 IS - 2 N2 - OBJECTIVE: There is a growing need to identify cerebrospinal fluid (CSF) markers that can detect Alzheimer's disease (AD) pathology in cognitively normal individuals because it is in this population that disease-modifying therapies may have the greatest chance of success. While AD pathology is estimated to begin ~10-15 years prior to the onset of cognitive decline, substantial neuronal loss is present by the time the earliest signs of cognitive impairment appear. Visinin-like protein-1 (VILIP-1) has demonstrated potential utility as a marker of neuronal injury. Here we investigate CSF VILIP-1 and VILIP-1/amyloid-β42 (Aβ42) ratio as diagnostic and prognostic markers in early AD. METHODS: We assessed CSF levels of VILIP-1, tau, phosphorylated-tau181 (p-tau181), and Aβ42 in cognitively normal controls (CNC) (n = 211), individuals with early symptomatic AD (n = 98), and individuals with other dementias (n = 19). Structural magnetic resonance imaging (n = 192) and amyloid imaging with Pittsburgh Compound-B (n = 156) were obtained in subsets of this cohort. Among the CNC cohort, 164 individuals had follow-up annual cognitive assessments for 2-3 years. RESULTS: CSF VILIP-1 levels differentiated individuals with AD from CNC and individuals with other dementias. CSF VILIP-1 levels correlated with CSF tau, p-tau181, and brain volumes in AD. VILIP-1 and VILIP-1/Aβ42 predicted future cognitive impairment in CNC over the follow-up period. Importantly, CSF VILIP-1/Aβ42 predicted future cognitive impairment at least as well as tau/Aβ42 and p-tau181/Aβ42. INTERPRETATION: These findings suggest that CSF VILIP-1 and VILIP-1/Aβ42 offer diagnostic utility for early AD, and can predict future cognitive impairment in cognitively normal individuals similarly to tau and tau/Aβ42, respectively. SN - 1531-8249 UR - https://www.unboundmedicine.com/medline/citation/21823155/Visinin_like_protein_1:_diagnostic_and_prognostic_biomarker_in_Alzheimer_disease_ L2 - https://doi.org/10.1002/ana.22448 DB - PRIME DP - Unbound Medicine ER -